Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) have earned an average recommendation of “Moderate Buy” from the eight analysts that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $25.00.

Several equities analysts have recently weighed in on PHAT shares. Guggenheim lifted their target price on shares of Phathom Pharmaceuticals from $20.00 to $25.00 and gave the company a “buy” rating in a report on Friday, February 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Phathom Pharmaceuticals in a report on Tuesday, April 21st. Barclays raised shares of Phathom Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $16.00 to $18.00 in a report on Friday, March 27th. Finally, Stifel Nicolaus set a $28.00 target price on shares of Phathom Pharmaceuticals in a report on Thursday, February 26th.

Institutional Investors Weigh In On Phathom Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd acquired a new stake in Phathom Pharmaceuticals in the 4th quarter valued at $27,000. Jones Financial Companies Lllp grew its stake in Phathom Pharmaceuticals by 442.6% in the 3rd quarter. Jones Financial Companies Lllp now owns 2,523 shares of the company’s stock valued at $30,000 after acquiring an additional 2,058 shares during the period. Raymond James Financial Inc. acquired a new stake in Phathom Pharmaceuticals in the 2nd quarter valued at $30,000. Summit Securities Group LLC acquired a new stake in Phathom Pharmaceuticals in the 1st quarter valued at $34,000. Finally, Kestra Advisory Services LLC acquired a new stake in Phathom Pharmaceuticals in the 4th quarter valued at $38,000. Institutional investors and hedge funds own 99.01% of the company’s stock.

Phathom Pharmaceuticals Trading Down 9.0%

PHAT opened at $11.87 on Friday. Phathom Pharmaceuticals has a 12-month low of $3.53 and a 12-month high of $18.31. The firm has a market capitalization of $946.75 million, a PE ratio of -5.60 and a beta of 0.57. The firm has a 50 day moving average of $11.63 and a two-hundred day moving average of $13.37.

Phathom Pharmaceuticals (NASDAQ:PHAT) last posted its earnings results on Thursday, February 26th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.01. The firm had revenue of $57.58 million for the quarter, compared to analysts’ expectations of $57.44 million. As a group, analysts predict that Phathom Pharmaceuticals will post -0.25 EPS for the current fiscal year.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals is a clinical‐stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The company’s core mission centers on addressing serious GI disorders by leveraging innovative mechanisms of action to improve patient outcomes. Phathom’s research and development efforts concentrate on conditions such as Helicobacter pylori infection, erosive esophagitis, gastroparesis and other functional GI disorders where significant unmet medical needs persist.

The company’s lead asset is vonoprazan, a potassium‐competitive acid blocker (P-CAB) licensed for use in the United States.